goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
headphones

HealthTree Podcast for Multiple Myeloma

HealthTree Podcast for MM

HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.

...more

not bookmarked icon
Share icon

All episodes

Best episodes

Top 10 HealthTree Podcast for Multiple Myeloma Episodes

Best episodes ranked by Goodpods Users most listened

play

01/06/22 • 51 min

A new approach in myeloma immunotherapies is in the works called Engineered Toxic Bodies (ETBs). Early on, Molecular Templates partnered with Takeda Oncology to begin development on an ETB therapy for multiple myeloma targeting CD38. Currently, Molecular Templates is moving this therapy forward. ETBs work differently from monoclonal antibodies because they move deep inside the plasma cell instead of flagging the cell's surface. They also don't rely on the body's own immune system (like T cells or NK cells) to kill myeloma. Learn more about this emerging therapy from Dr. Shaji Kumar on this fascinating program. Thanks to our episode sponsor, Takeda Oncology
play

01/06/22 • 51 min

bookmark
plus icon
share episode
play

01/05/22 • 69 min

Join Dr. Dan Vogl and Dr. Yulia Nefedova to understand more about a new oral treatment for multiple myeloma called tasquinimod. This is a treatment that targets the tumor microenvironment by targeting myeloid-derived suppressor cells (MDSCs). MDSCs are a variety of cells that expand during cancer, inflammation and infection, and can suppress T-cell responses. They can stop myeloma killing-immune cells and at the same time form new tumor blood vessels that help myeloma spread in the body. The researchers are hopeful that tasquinimod will promote anti-tumor immune activity . The treament is being developed by a Swedish company called Active Biotech and tasquinimod is now being tested in combination with standard myeloma therapies like lenalidomide, ixazomib and dex. New treatments like these could be used in patients who have relapsed after standard myeloma treatment like daratumumab and could help alter the microenvironment that is causing myeloma relapse. Thanks to our episode sponsor, Bristol Myers Squibb
play

01/05/22 • 69 min

bookmark
plus icon
share episode

Myeloma Crowd Radio: Elisabet Manasanch, MD, MD Anderson

HealthTree Podcast for Multiple Myeloma

play

10/27/21 • 64 min

Smoldering myeloma is a precursor condition for the blood cancer multiple myeloma. There is hot debate about when and how to treat this precursor condition. Do you treat it like regular myeloma? Do you try to prevent progression? And if so, with which therapies? Dr. Elisabet Manasanch of the MD Anderson Cancer Center provides an update on treatment in smoldering myeloma and smoldering myeloma clinical trial designs that seek to determine the very best approach. Thanks to our episode sponsor, Bristol Myers Squibb
play

10/27/21 • 64 min

bookmark
plus icon
share episode
play

10/04/21 • 73 min

All cancer therapies come with some type of side effect. One newly approved therapy called BLENREP, by GSK, is an antibody drug conjugate targeting BCMA that can cause a condition called keratopathy. Keratopathy is an eye condition that can be mild, so patients don't even know they have it, or it can be more severe. Myeloma specialist Dr. Cristina Gasparetto, MD from Duke University and Mark Newman, OD of OPTIX Eye Center will share in this show how keratopathy can be successfully managed for patients on BLENREP. Learn what keratopathy is, how care is coordinated between the myeloma doctor and the eye doctor, and what patients should know about keratopathy before starting on this therapy. Thanks to our episode sponsor, Takeda Oncology
play

10/04/21 • 73 min

bookmark
plus icon
share episode
play

05/18/21 • 64 min

Myeloma experts are beginning to use antibodies in earlier lines of myeloma treatment, even for newly diagnosed patients. Learn what recent clinical trials are using antibody therapies such as daratumumab and isatuximab in early quad (four) drug combinations for newly diagnosed patients. Peter Voorhees of the Levine Cancer Institute joins Myeloma Crowd Radio to share his experience and findings from these clinical trials. He will discuss the early use and their use as maintenance therapy following stem cell transplant. Is earlier use better? Should they be "saved" for later? When should patients consider using the monoclonal antibodies as maintenance therapy with or without traditional drugs like lenalidomide? Dr. Voorhees will help answer these very practical questions for the myeloma community. Thanks to our episode sponsor, Karyopharm Therapeutics.
play

05/18/21 • 64 min

bookmark
plus icon
share episode
play

05/14/21 • 62 min

AL Amyloidosis is a secondary condition that can occur in patients with multiple myeloma and can cause protein buildup in organs like the heart, kidneys, liver and nerves. Join Myeloma Crowd Radio by HealthTree to hear from Sascha Tuchman, MD of the University of North Carolina at Chapel Hill as he shares amyloidosis symptoms, treatments and open clinical trials. Thanks to our episode sponsor, Takeda Oncology
play

05/14/21 • 62 min

bookmark
plus icon
share episode
play

04/16/21 • 62 min

CAR T therapy has been in development for over 20 years. The first CAR T therapy is now available for the treatment of multiple myeloma. The ide-cel treatment (now called Abecma) is now FDA approved for multiple myeloma relapsed or refractory patients. In this show, Dr. Noopur Raje of Mass General Hospital will share how the CAR T cell therapy works, outcome data from clinical trials, a review of patients who are eligible to join and when patients should consider the therapy in context of other therapies. Ide-cel (Abecma) is a product developed by Bristol Myers Squibb and blubird bio. Thanks to our episode sponsor, Oncopeptides
play

04/16/21 • 62 min

bookmark
plus icon
share episode
play

01/22/21 • 84 min

Dr. Robert Z. Orlowski joins Myeloma Crowd Radio to share a study to share the new innovations myeloma patients can expect in 2021. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2021, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smoldering myeloma. We invite you to join us for this well loved annual show. Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Board of Hematology and the Journal of Clinical Oncology. Dr. Orlowski has received many awards over a number of years including the Leukemia & Lymphoma Society Scholar in Clinical Research, the Leukemia & Lymphoma Society’s Man of the Year Award, Emil Frei III Award for Excellence in Translational Research from MD Anderson and is the recipient of an ongoing SPORE grant from the NIH. Find news and information from his daily newspaper, Myeloma Daily or find him on Twitter at @myeloma_doc. Thanks to our episode sponsor, Karyopharm Therapeutics
play

01/22/21 • 84 min

bookmark
plus icon
share episode
play

12/16/20 • 64 min

Dr. Irene Ghobrial joins Myeloma Crowd Radio to share a study to identify discoveries that could potentially inform COVID-19 treatment decisions and prevention policies in the IMPACT study. Myeloma patients are known to be immunocompromised and may be at higher risk for poor outcomes. IMPACT is a study to identify the prevalence and unique characteristics of COVID-19 in individuals with precursor conditions to hematologic malignancies and in healthy populations. It is enrolling individuals nationwide who are enrolled in the PCROWD and PROMISE studies. All participants enrolled in IMPACT are screened using a blood test for active SARS-CoV-2 and/or antibodies. Participants are then followed and undergo additional blood collection and testing over a one-year period. The overall goal of IMPACT is to understand the short- and long-term impact of COVID-19 on the immune system of healthy individuals and individuals with underlying immune dysregulation. Thanks to our episode sponsor, Bristol Myers Squibb
play

12/16/20 • 64 min

bookmark
plus icon
share episode
play

02/07/22 • 69 min

Dr. Robert Z. Orlowski joins Myeloma Crowd Radio to share a study to share the new innovations myeloma patients can expect in 2022. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2022, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smoldering myeloma. We invite you to join us for this well loved annual show. Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Board of Hematology and the Journal of Clinical Oncology. Dr. Orlowski has received many awards over a number of years including the Leukemia & Lymphoma Society Scholar in Clinical Research, the Leukemia & Lymphoma Society’s Man of the Year Award, Emil Frei III Award for Excellence in Translational Research from MD Anderson and is the recipient of an ongoing SPORE grant from the NIH. Find news and information from his daily newspaper, Myeloma Daily or find him on Twitter at @myeloma_doc. Thanks to our episode sponsor, Bristol Myers Squibb
play

02/07/22 • 69 min

bookmark
plus icon
share episode

Show more

Toggle view more icon

FAQ

How many episodes does HealthTree Podcast for Multiple Myeloma have?

HealthTree Podcast for Multiple Myeloma currently has 210 episodes available.

What topics does HealthTree Podcast for Multiple Myeloma cover?

The podcast is about Health & Fitness and Podcasts.

What is the most popular episode on HealthTree Podcast for Multiple Myeloma?

The episode title 'Myeloma Crowd Radio: Shaji Kumar, MD, Mayo Clinic on ETBs in Myeloma' is the most popular.

What is the average episode length on HealthTree Podcast for Multiple Myeloma?

The average episode length on HealthTree Podcast for Multiple Myeloma is 67 minutes.

How often are episodes of HealthTree Podcast for Multiple Myeloma released?

Episodes of HealthTree Podcast for Multiple Myeloma are typically released every 10 days, 4 hours.

When was the first episode of HealthTree Podcast for Multiple Myeloma?

The first episode of HealthTree Podcast for Multiple Myeloma was released on Jul 5, 2013.

Show more FAQ

Toggle view more icon

Comments

0.0

out of 5

Star filled grey IconStar filled grey IconStar filled grey IconStar filled grey IconStar filled grey Icon
Star filled grey IconStar filled grey IconStar filled grey IconStar filled grey Icon
Star filled grey IconStar filled grey IconStar filled grey Icon
Star filled grey IconStar filled grey Icon
Star filled grey Icon

No ratings yet